Desfibrilador automático en la miocardiopatía hipertrófica. Experiencia de 3 centros

Marı́n, Francisco; Gimeno, Juan R.; Payá, Eduardo; García‐Alberola, Arcadio; Pérez-Álvarez, Luisa; Fernández, Xusto; Morena, Gonzalo de la; Sogorb, Francisco; Castro‐Beiras, Alfonso; Valdés, Mariano; Martínez, Juan G.; Monserrat, Lorenzo

doi:10.1157/13089740

Cited by 23 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intervention rates, age at implant and percentage of primary prevention patients in both multicentre studies are consistent with those reported from other countries, including Spain 18,19 , Poland 20 , United Kingdom 21 , Australia 22 , and other U.S. centers 23 ( Table 1 )…”

Section: Evidence Of Icd In Hcmsupporting

confidence: 86%

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy

Sanchez

Fernández‐Lozano

2018

gcsp

View full text Add to dashboard Cite

Sudden cardiac death (SCD) is the most devastating complication in hypertrophic cardiomyopathy (HCM). The implantable cardioverter–defibrillator (ICD) has proven to be effective in SCD prevention in several clinical scenarios. In HCM population, it has demonstrated to successfully abort life-threatening ventricular arrhythmias despite the extreme morphology characteristic of HCM, often with massive degrees of left ventricular hypertrophy and/or LV outflow tract obstruction. Studies showed a high rate of appropriate intervention in secondary prevention and in primary prevention of patients considered at high risk. This appropriate intervention rate is even more significant considering the young and otherwise healthy patients that compose HCM population. Since SCD incidence in HCM is relatively low, optimal identification of patients at high risk is crucial. Classical strategy of risk stratification based on clinical risk factors has several limitations and has proven to overestimate risk. A new risk prediction model that provides individual 5-year estimated risk appears to be superior to traditional models based on bivariate risk factors. Perioperative complications seem to be similar to those related to the implant of other cardiac devices, while long-term complications have been traditionally in the spotlight. HCM patients are considered more vulnerable to ICD-related complications and inappropriate ICD therapy because of their young age at implant and increased prevalence of atrial fibrillation, but long-term follow-up data on ICD-related complications in general practice is limited. The subcutaneous implantable cardioverter defibrillator seems to be a safe and effective alternative in HCM, although long-term data are scarce.

show abstract

Section: Evidence Of Icd In Hcmsupporting

confidence: 86%

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy

Sanchez

Fernández‐Lozano

2018

gcsp

View full text Add to dashboard Cite

show abstract

“…Few data are available on the follow-up of patients who receive an ICD following the indications of these guidelines. [13][14][15] The aim of the present study was to analyze the follow-up of patients with HCM who received an ICD in the routine clinical practice setting in 3 centers normally attending patients with this disease.…”

Section: Introductionmentioning

confidence: 99%

Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention

Sarrias

Galve

Sabaté

et al. 2015

Revista Española de Cardiología (English Edition)

View full text Add to dashboard Cite

Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Maron¹,

Spirito²,

Shen³

et al. 2007

JAMA

689

594

View full text Add to dashboard Cite

HE RISK OF SUDDEN DEATH IN PA-tients with hypertrophic cardiomyopathy (HCM) has been known for almost 50 years. [1][2][3][4][5][6] Indeed, this disease is the most common cause of sudden cardiac death in young people, 1-6 including trained athletes. 7 However, only in the last few years has the implantable cardioverterdefibrillator (ICD) been systematically used as a potentially life-saving For editorial comment see p 452.

show abstract

Desfibrilador automático en la miocardiopatía hipertrófica. Experiencia de 3 centros

Cited by 23 publications

References 37 publications

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy

Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention

Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Contact Info

Product

Resources

About